“As I said before, we should be exploring strategic alliances to get LL included as apart of Long Covid treatment rather than launching a trial were we will probe that we indeed do some good but were meeting significant EP might probe to be very difficult due to the fact that Long Covid needs to be attacked from several fronts.”

Great post TG. As I’ve said before, IMO, CYDY has been approached in the past for partnerships for HIV and COVID. I believe NP’s pride prevented those partnerships from occurring. The Vyera deal is an anomaly and not the standard, so yes, a partnership with BP would be in the 20% range. CYDY needs the revenues and the name recognition. The same goes for longhaulers. Some investors disagree, but 100% of zero is zero and we know BP has a track record of getting drugs to the market (R&D, lobbyist, etc.).